Funding Support Center
DF/HCC Sponsored Funding
Dana-Farber/Harvard Cancer Center (DF/HCC) Sponsored Funding
Sponsor: Non-federal (DFCI)
One page Letter of Intent due by February 28, 2013. Submit letter online: Application Form Web Page
Submission requirements: Applications must be submitted online: Application Form Web Page
Please direct questions to:
Disparity Research Awards provide support for up to two years for research projects aimed at understanding and eliminating racial, ethnic, and socioeconomic disparities in prostate cancer. This RFA will address prostate cancer disparities as differences in the incidence, prevalence, mortality, and burden of prostate cancer and related adverse health conditions on specific population groups. Research should focus on factors that contribute to prostate cancer disparities including interactions of the social and physical environment, behavioral factors, and/or biologic/molecular pathways. Research teams will seek to understand the complexity of health disparities rather than single factor relationships. Projects should develop preliminary data necessary to prepare and submit a competitive research grant application to a major funding agency.
Award is for $50,000 per year for up to two years ($100,000 total in direct costs). The next projected award period is August 1, 2013 to July 31, 2015. One award remains available in this category to be awarded over a two-year period.
The Mazzone Awards Program is a DFCI sponsored award, administered jointly through DF/HCC and the Prostate Cancer Foundation.
Applications will be accepted from two or more independent investigators, at least one of whom holds a full-time Harvard faculty appointment at the level of Instructor or higher. Applications including investigators from more than one DF/HCC member institution are encouraged, as are applications that are part of the University of Massachusetts Boston-DF/HCC U54 partnership. Applicants from institutions throughout the country are encouraged to apply as long as they have a collaborator in one of the DF/HCC institutions. Applicants may apply for multiple grants; however, individuals may only be awarded one A. David Mazzone Research Award at a time.
Employees or subcontractors of a government entity or for-profit private industry are not eligible. Exceptions include applicants holding full-time positions at a veterans' hospital or national laboratory (e.g., Lawrence Berkeley National Laboratory) in the United States. Members of the Programís Scientific Advisory Board (SAB) are ineligible to apply.
PROPOSAL SUBMISSION INFORMATION
Format: Items 2 Ė 4 (above) must be compiled and submitted as a single PDF file. Please include the PIís name, project title, and page number at the top of each page.
Submit Proposal Online: Application Form Web Page
2012 disparities research Mazzone Awards Recipients
Estimating The Prostate Cancer Burden Attributed To Lifestyle And Genetic Factors Among African-American And White Men
PI: Lorelei Mucci (Harvard School of Public Health)
African-American men have the highest rates of prostate cancer in the world, 60 times greater than men in low risk countries (Japan and China). In the US, African-American men are 1.6 times more likely to be diagnosed with and 2.4 times more likely to die from prostate cancer than Caucasian men. Even with equal access to equal care, African-American men still experience a greater burden of prostate death and suffering due to epidemiological and genetic differences we do not yet fully understand. For this proposal, we focus on lifestyle and genetic factors that may explain part of the undue burden of prostate cancer in African-American men. In Aim 1, we select 10 factors based on their known or suspected role in the development or progression of prostate cancer, as well as that their prevalence differs across populations. Using data from two prospective cohorts, we will estimate the proportion of prostate cancer attributable to these 10 factors and calculate the proportion of disease and mortality that might be preventable among both African-American and Caucasian men. In Aim 2, we leverage a unique tumor biorepository within the cohorts and perform gene-expression profiling on the tumors of 20 African-American and 200 Caucasian men with prostate cancer. We undertake gene-set and pathway based and compare and contrast mRNA profiles among African-American and Caucasian men. Prevention holds the greatest promise to reduce suffering from prostate cancer. This proposal has the potential to identify the underpinnings of disparities and illuminate novel opportunities for prevention.
Biorepositories are a key resource for translational research. However, the benefits of research conducted with biobanked materials is likely to accrue largely to populations who are well-represented in biobanks. Given the significant and long-standing disparities, the lack of representation of Blacks in most biorepositories is of great concern. There has been little exploration of the factors associated with biobanking participation among Blacks. Further, if efforts to increase awareness and understanding about biobanking are focused in academic health centers, we will miss a large proportion of the Black community. The goal of the proposed study is to develop and evaluate an educational approach to increase knowledge about and willingness to consider participation in biorepositories among Blacks. NCI has developed the Minority Biospecimen/Biobanking - Geographic Management Program (BMaP), which is testing the feasibility of developing minority biobanks. The proposed work will be coordinated with BMaP and will ensure that as minority biobanks are developed, the concerns of Black men with and at-risk for prostate cancer can be considered. This study has elements of both disparities research and outreach, but is submitted for the disparities research mechanism because it represents basic population science research that will increase our understanding of menís knowledge of biobanking, and will evaluate an intervention to improve knowledge and intention outcomes. Outreach and education is conducted as part of this project, but is not the primary focus of the research.
2011 disparities research Mazzone Awards Recipients
Enhancing Usability of the Personal Patient Profile-Prostate (P3P) for Black and Hispanic Men
Selecting treatment is a daunting task for men with newly diagnosed localized prostate cancer (LPC). No single treatment option is clearly superior in terms of efficacy and morbidity. There is a growing body of evidence that men with a recent diagnosis of LPC engage in the treatment decision making process by strongly considering their personal factors along with medical factors. The research team has developed and tested the Personal Patient Profile-Prostate (P3P), the first automated, tailored and efficacious intervention to support men with LPC. The team has evidence that P3P significantly decreases decisional conflict over 6 months after diagnosis; yet found higher decisional conflict in minority men. While the randomized trial included a diverse sample, the earlier pilot work was conducted in a predominantly White sample. Intensive usability evaluations in minority men, conducted parallel to the trial, suggested additional development needs for both the English and Spanish versions of P3P. Therefore, the teamís aim is to improve the a) linguistic and contextual appropriateness of P3P content; and b) technical usability for Black and Hispanic men. We will refine the P3P user interface to enhance usability and acceptability while being careful to not change the nature of the intervention. To address these issues, the team will employ an established iterative development process with a sample of 20 Black and 20 Hispanic men with a recent diagnosis of LPC. The goal is to measure: a) program content reading level; b) health literacy; c) navigation of the program; d) usability and e) acceptability.
Understanding Racial Differences in Prostate Cancer Mortality
This study seeks to explain the black-white racial gap in prostate cancer mortality and identify clinical and social opportunities to reduce those disparities. Racial gaps in prostate cancer mortality are among the largest in any disease, yet remain incompletely explained. In year 1, the study will decompose the racial gap in prostate cancer mortality into differential incidence and stage-specific survival using SEER-Medicare data for prostate cancer patients and controls. The study can then attribute the racial gap in stage-specific incidence to disparities in PSA testing, comorbidities, and income. Then, the study will analyze how tumor characteristics, differential receipt of tests and treatments, access to different physicians, and socioeconomic differences impact the racial gap in survival. In year 2, the study will consider how differential vitamin intake may affect racial differences in prostate cancer incidence.